WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE
Boulder
1155 Canyon Blvd.
Suite 400
Boulder 80302-5195
US

T303-256-5900

About Our Boulder Office

Wilson Sonsini's office in downtown Boulder supports the region’s thriving life sciences businesses and other growth enterprises. It features a core team that includes several partners, associates, and staff professionals—most of whom have strong ties to companies, universities, and business organizations in the Colorado area. The firm expects the office to grow based on clients’ needs, the strength of the market in the region, and related recruiting efforts.

Wilson Sonsini already represents clients in Colorado that fall into a range of life sciences sectors, including: drug discovery; biotech, genomics, and proteomics; screening and diagnostics; medical devices and supplies; pharmaceuticals; health services; and agtech and foodtech. In fact, the firm has advised on a number of recent life sciences venture capital financings, M&A transactions, and IPOs in the region, including the IPO of Edgewise Therapeutics, a leader in the search for lifesaving medicines for rare muscular disorders, and the Series A financing for Foresight Diagnostics, which has developed promising technology for the early detection of cancers.

The firm also represents other technology companies based in Colorado and throughout the region, including innovative companies such as Solid Power, an industry-leading developer of all-solid-state battery cells for electric vehicles, and Inspirato LLC, an innovative luxury travel subscription brand. Please see the Related News and Insights section below for more information.

Get Directions
Related News and Insights
Client Highlights
Wilson Sonsini Advises Renovare Therapeutics on Company Launch and Collaboration with CU Boulder
On April 6, 2026, Renovare Therapeutics, a privately held biotechnology company pioneering regenerative therapeutics for osteoarthritis, announced its formal launch from stealth mode and collaboration with University of Colorado (CU) Boulder. Wilson Sonsini Goodrich & Rosati advised Renovare Therapeutics on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Ambrosia Biosciences on $100 Million Oversubscribed Series B Financing
On March 31, 2026, Ambrosia Biosciences, Inc., a privately held drug discovery company, announced a $100 million oversubscribed Series B preferred stock financing. The round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.
Learn More
Newsletters
The Life Sciences Report – January 2026
This latest edition features articles on reasons for optimism around 2026 life sciences fundraising, key IP priorities for biotech and biopharma following Series B financing, the default rules of joint patent rights worldwide, the evolving role of innovation theories of harm in the antitrust analysis of life science mergers, life sciences venture financings for firm clients across 2H2024 and 1H2025, and how Wilson Sonsini helped ensure Light Horse Therapeutics’ impressive debut. The report also includes details on the most recent Biotech Summit and Phoenix Conference, the LaunchBio East Coast NextGen VC Forum, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and the Patents and Innovations Library for in-house IP counsel, as well as select life sciences client highlights and upcoming events.
Learn More
Newsletters
The Entrepreneurs Report: Private Company Financing Trends – Q3 2025
Wilson Sonsini is pleased to present the Q3 2025 edition of The Entrepreneurs Report. We’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the third quarter, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
Learn More
Newsletters
The Life Sciences Report – June 2025
This latest edition features articles on succeeding in the current life sciences funding market, strategic and legal considerations in digital health combinations, the corporate practice of medicine and guidance for healthcare companies and investors, the FDA’s plan to phase out animal testing, and life sciences venture financings for clients in 2024. The newsletter also includes details on the firm’s additions of leading digital health attorney and former HHS policymaker Jodi Daniel and USPTO veteran Jean Witz, the recent LaunchBio West Coast NextGen VC Forum and Life Sciences Investment Forum, Wilson Sonsini’s LSPN “Life Sciences IP Firm of the Year” award and sponsorship of the National Inventors Hall of Fame Induction Ceremony, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and the Patents and Innovations Learning Library for in-house IP counsel, as well as select life sciences client highlights, recent webinars, and upcoming events.
Learn More
Newsletters
The Entrepreneurs Report - Full-Year 2024
In this latest edition, we’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during 2024. This issue includes a Market Perspective segment with Wilson Sonsini partner Amy Caiazza, leader of Wilson Sonsini’s fintech and financial services group, who offers her thoughts on the recent crypto boom and the regulatory environment of 2025.
Learn More
View All Related News and Insights
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.